within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AL05_FormoterolAndAclidiniumBromide;

model FormoterolAndAclidiniumBromide
  extends Pharmacolibrary.Drugs.ATC.R.R03AL05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R03AL05</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Formoterol and aclidinium bromide is a fixed-dose combination inhalation medication comprising a long-acting beta2-agonist (formoterol) and a long-acting muscarinic antagonist (aclidinium) used in the maintenance treatment of chronic obstructive pulmonary disease (COPD). Both substances act by relaxing airway smooth muscle and inhibiting bronchoconstriction to help maintain open airways. The combination is approved and in current use for COPD management.</p><h4>Pharmacokinetics</h4><p>No population pharmacokinetic studies directly examining the combination product were found in the literature. Parameters below are estimated based on the published PK parameters of individual drugs (inhaled formoterol and aclidinium) in healthy adults. Model assumes one-compartment kinetics and standard inhalation administration.</p><h4>References</h4><ol><li><p>Lal, C, &amp; Strange, C (2015). Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease. <i>Expert opinion on pharmacotherapy</i> 16(3) 427–434. DOI:<a href=\"https://doi.org/10.1517/14656566.2015.1000861\">10.1517/14656566.2015.1000861</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25597386/\">https://pubmed.ncbi.nlm.nih.gov/25597386</a></p></li><li><p>Malerba, M, et al., &amp; Montuschi, P (2018). The discovery and development of aclidinium bromide for the treatment of chronic obstructive pulmonary disease. <i>Expert opinion on drug discovery</i> 13(6) 563–577. DOI:<a href=\"https://doi.org/10.1080/17460441.2018.1455661\">10.1080/17460441.2018.1455661</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29616842/\">https://pubmed.ncbi.nlm.nih.gov/29616842</a></p></li><li><p>Fuhr, R, et al., &amp; Aubets, J (2016). Pharmacokinetics of aclidinium bromide/formoterol fumarate fixed-dose combination compared with individual components: A phase 1, open-label, single-dose study. <i>Clinical pharmacology in drug development</i> 5(2) 109–117. DOI:<a href=\"https://doi.org/10.1002/cpdd.209\">10.1002/cpdd.209</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27138024/\">https://pubmed.ncbi.nlm.nih.gov/27138024</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end FormoterolAndAclidiniumBromide;
